| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T22095 | ||||
| Target Name | Interleukin-17 | ||||
| Target Type | Successful |
||||
| Action against Disease Model | Secukinumab | AIN457 significantly down-regulated IL-6 production (-25+7%; p<0.05) in MM-BMSC co-culture. We also observed that AIN-457 significantly reduced adhesion of MM cells to stromal cells (27%, p=0.011). AIN457 significantly inhibited IL-6 production in h uMan fetal bone chips in the presence of MM cells within 24 hours of ex-vivo culture (control - 487+39 pg/ml; IL-17 990+27 pg/ml; p<0.01 and AIN-457 - 326+7 pg/ml; p<0.01). | Drug Info | ||
| The Effect of Target Knockout, Knockdown or Genetic Variations | Gene deletion resulted in Eosinophilia decrease, Airway hyperresponsiveness and Immune response decrease compared to wild type | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.